In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Read the full coverage here:

Blue-collar workers more likely to miss work, quit due to psoriatic arthritis

Infliximab biosimilar uptake rapidly increased only after release of a third option

National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala

Safety checklist compiles clinically important DMARD warnings in one place

Guselkumab demonstrates long-term efficacy, safety in psoriasis

References:

Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.

Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.

Press Release

Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.

Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen ‘merits further study’ for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more.

Read the full coverage here:

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema

OCS-01 eye drop for DME in second stage of phase 3 trial

Q&A: Susvimo delivers immediate durability after implantation in wet AMD

References:

Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Press Release

Press Release